Trial
NCT03493412
Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Nebraska
Collaborators
—
Condition
Peripheral Artery Disease
Intervention
Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
Why stopped
discontinued due to change in operating plans prior to study initiation and enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-03